Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean glycol and hyaluron acid non animalis stabilized and ratinal?
Displaying drugs 2001 - 2025 of 15188 in total

Artemisia vulgaris root

Artemisia vulgaris root allergenic extract is used in allergenic testing.
Approved
Investigational
Matched Categories: … Non-Standardized Food Allergenic Extract …

Diloxanide furoate

Approved

Zolmitriptan

Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)1B/1D/(1F) receptor agonists used to treat acute migraine.[A462, L12978] Sumatriptan was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, and zolmitriptan. Triptans...
Approved
Investigational
Matched Description: … It is currently available in both tablet and nasal spray forms.[L12978] ... A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and ... [A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent …
Matched Categories: … Serotonin-1b and Serotonin-1d Receptor Agonist …

Ganciclovir

An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Approved
Investigational
Matched Categories: … Nucleic Acid Synthesis Inhibitors ... Ganciclovir and prodrug ... Nucleosides and Nucleotides ... Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors …

Prucalopride

Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC...
Approved
Matched Description: … prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target ... A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018. ... [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[ …
Matched Categories: … Alimentary Tract and Metabolism …

Desflurane

Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as methoxyflurane, sevoflurane, enflurane, or isoflurane.[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted...
Approved
Matched Description: … Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than ... It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled …

Trimetazidine

Trimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Trimetazidine has been studied as a treatment for angina pectoris since the late 1960s.[A233255,A233260] Acidic conditions, caused by anaerobic metabolism and fatty acid oxidation, in response...
Approved
Investigational
Matched Description: … [A233255,A233260] Acidic conditions, caused by anaerobic metabolism and fatty acid oxidation, in response ... to myocardial ischemia, activate sodium-hydrogen and sodium-calcium antiport systems. ... It is hypothesized that trimetazidine inhibits 3-ketoacyl coenzyme A thiolase, which decreases fatty acid …

Roxadustat

Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. Roxadustat was first approved...
Approved
Investigational
Matched Iupac: … 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)formamido]acetic acid …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Sertraline

Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before...
Approved
Matched Description: … is similar to drugs such as [Citalopram] and [Fluoxetine]. ... popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and ... classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and …

Ozenoxacin

To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by Staphylococccus aureus or Streptococcus pyogenes in adult and pediatric patients...
Approved
Investigational
Matched Iupac: … cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …
Matched Description: … and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone that ... has demonstrated safe and effective therapy in both the adult and pediatric population. ... pediatric patients 2 months of age and older. …

Icatibant

Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B2 receptors with a similar affinity to bradykinin. It is resistant to bradykinin-cleaving enzyme degradation and has a potency of 2-3 times higher than earlier B2 receptors antagonists, thus representing a new class of medication.[A4017,A263041] It was...
Approved
Investigational
Matched Description: … Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the Band has a potency of 2-3 times higher than ... [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a …
Matched Categories: … Analgesics, Non-Narcotic ... Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Anthoxanthum odoratum

Anthoxanthum odoratum allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Non-Standardized Food Allergenic Extract …

Lactulose

Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929 , investigations regarding its possible use as a laxative for...
Approved
Matched Description: … a readily available generic and brand-name non-prescription medication listed on the World Health Organization's ... possible use as a laxative for the treatment of chronic constipation did not occur until the 1960s and ... [L6202] Nevertheless, although lactulose received formal FDA approval in 1977 and has since become …
Matched Categories: … Alimentary Tract and Metabolism …

Arbutin

Extracted from the dried leaves of bearberry plant in the genus Arctostaphylos and other plants commonly in the Ericaceae family, arbutin is a beta-D-glucopyranoside of DB09526. It is found in foods, over-the-counter drugs, and herbal dietary supplements . Most commonly, it is an active ingredient in skincare and cosmetic products...
Approved
Matched Description: … of melanin synthesis at non-toxic concentrations was observed _in vitro_. ... and [DB09526] [F43]. ... It is found in foods, over-the-counter drugs, and herbal dietary supplements [F43]. …

Aldesleukin

Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from...
Approved
Matched Description: … Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression ... because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid ... during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Interferon alfa-2a

Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is...
Approved
Investigational
Matched Description: … A type I interferon consisting of 165 amino acid residues with lysine in position 23. ... This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Temozolomide

Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these...
Approved
Investigational
Matched Description: … guanine bases leading to DNA lesions and eventual apoptosis. ... malignant brain tumours with poor prognosis and limited treatment options. ... Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Succinylcholine

Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter acetylcholine (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. Its...
Approved
Matched Description: … Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and ... A299] most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and …

Bordetella pertussis fimbriae 2/3 antigen

Bordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct fimbriae (Fim2 and Fim3).
Approved
Investigational
Matched Description: … pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct fimbriae (Fim2 and …
Matched Mixtures name: … FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS PERTACTIN ANTIGEN, and …

Ferric sulfate

Ferric sulfate has the molecular formula of Fe2SO4, and it is a dark brown or yellow chemical agent with acidic properties. It is produced by the reaction of sulfuric acid and an oxidizing agent. It is used in different fields such as dermatology, dentistry and it is thought to present...
Approved
Matched Description: … It is produced by the reaction of sulfuric acid and an oxidizing agent. ... Ferric sulfate has the molecular formula of Fe2SO4, and it is a dark brown or yellow chemical agent with ... It is used in different fields such as dermatology, dentistry and it is thought to present hemostatic …

Elacestrant

Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.[A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.[L44918,L44948] It received a similar approval in the EU in September 2023. Elacestrant binds to estrogen receptor-alpha (ERα)...
Approved
Investigational
Matched Description: … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. ... degrader (SERD) thanks to its ability to block the transcriptional activity of the ER and promote its ... [L49334] Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor …
Matched Categories: … Estrogens, Non-Steroidal ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents …

Fluvastatin

Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It...
Approved
Matched Iupac: … (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid …
Matched Description: … HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol ... levels and prevent cardiovascular disease. ... Fluvastatin is a racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin. …

Sulfinpyrazone

A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Approved
Matched Description: … It lacks anti-inflammatory, analgesic, and diuretic properties. …
Matched Categories: … Preparations Increasing Uric Acid Excretion …

Asfotase alfa

Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth. By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels...
Approved
Investigational
Matched Description: … morbidity and premature death. ... Food and Drug Administration (FDA) on October 23, 2015. ... 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved by …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Etravirine

Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of...
Approved
Matched Description: … Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase ... consequently blocks DNA-dependent and RNA-dependent polymerase activity. ... effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and …
Matched Categories: … Nucleic Acid Synthesis Inhibitors ... Non-Nucleoside Reverse Transcriptase Inhibitors ... Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor …
Displaying drugs 2001 - 2025 of 15188 in total